PRINCETON, N.J., June 25 /PRNewswire-FirstCall/ —
Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the
Company), a late-stage biopharmaceutical company, announced today
the publication of an article in the June
2010 edition of Vaccine, which describes protection
from mucosal and systemic ricin intoxication by intradermal
administration of RiVax™, the Company’s vaccine
against ricin toxin. The article was authored by the Company’s
collaborators at the University of Texas
Southwestern Medical Center at Dallas (UT Southwestern)
where the vaccine originated. RiVax™ is currently being
evaluated in Phase 1 human safety and immunogenicity trials, as
well as non-human primate trials for efficacy.
The purpose of this study was to determine whether RiVax™
administered by intradermal (ID) injection would be more
immunogenic and protective at lower doses. ID vaccination has
several practical advantages in protecting humans due to the ease
of administration, especially when using an ID gun, thereby
eliminating the need for needles and subsequent needle disposal. In
this publication, a comparison of ID and intramuscular (IM)
vaccination with or without an aluminum salt adjuvant at several
dose levels was investigated. The levels of anti-RiVax™
antibodies generated in serum as well as the ability of the vaccine
to protect mice against ricin intoxication following systemic,
gastric gavage or aerosol challenges were determined.
The major findings to emerge from this study are as follows:
- ID vs. IM administration of RiVax™ without
adjuvant conferred equal protection; - RiVax™ adsorbed to aluminum adjuvant was significantly
better than RiVax™ alone in eliciting speci‘/>”/>
